RFA plus lyso-thermosensitive liposomal doxorubicin: In search of the optimal approach to cure intermediate-size hepatocellular carcinoma

Riccardo Lencioni, Dania Cioni

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

When heated during a radiofrequency ablation (RFA) procedure to ≥40�C, lyso-thermosensitive liposomal doxorubicin (LTLD) produces high drug concentration in the surrounding margins of the ablation zone. The hypothesis that the RFA + LTLD combination can effectively treat hepatocellular carcinoma (HCC) was investigated in the HEAT study: adding LTLD did not improve the efficacy of normal practice RFA. However, among the 285 patients with a solitary lesion who received at least 45-min RFA dwell time, the hazard ratio for overall survival was 0.63 (95% CI: 0.41-0.96; p = 0.04). The OPTIMA study is currently ongoing to test the hypothesis that adding LTLD to a standardized RFA lasting ≥45 min increases survival compared with standardized RFA alone.

Original languageEnglish (US)
Pages (from-to)193-200
Number of pages8
JournalHepatic Oncology
Volume3
Issue number3
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

    Fingerprint

Keywords

  • hepatocellular carcinoma
  • lyso-thermosensitive liposomal doxorubicin
  • radiofrequency ablation

ASJC Scopus subject areas

  • Hepatology
  • Oncology

Cite this